Kintor Pharmaceutical
Presence
Kintor Pharmaceutical is a company listed under the stock ticker 9939 (CN).
Executives
View the org chart displaying its 14 main executives
Most searched biographies at Kintor Pharmaceutical
- Youzhi Tong, Chief Executive Officer and Chairman of the Board
- Wei Geqi, Non-Executive Director
- Gao Weipeng, Non-Executive Director
Create your alert
to follow the executive moves at Kintor Pharmaceutical.
Pharmaceuticals
Kintor Pharmaceutical has 1,861 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Kintor Pharmaceutical
- Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US_Kintor Pharmaceutical Limited
- Kintor Pharma Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematologic Malignancies in China_Kintor Pharmaceutical Limited
- Kintor Pharma Announces Completion of First Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China_Kintor Pharmaceutical Limited
- Kintor Pharma Announces 2022 Annual Results and Recent Business Progress _Kintor Pharmaceutical Limited
- Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China_Kintor Pharmaceutical Limited
- Kintor Pharma’s KX-826 and GT20029 for Treatment of Androgenetic Alopecia (AGA) and Acne Presented at AAD 2023 _Kintor Pharmaceutical Limited
- Kintor Pharma Announces Preclinical Data of GT1708F at AACR 2023_Kintor Pharmaceutical Limited
- Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound_Kintor Pharmaceutical Limited
- Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Female Androgenetic Alopecia in China Was Met_Kintor Pharmaceutical Limited
- Kintor Pharma Announced Completion of Phase I Trial of the World’s First PROTAC Compound (GT20029) for Topical Use_Kintor Pharmaceutical Limited
- View more press releases Close
Social media about Kintor Pharmaceutical
- Kintor Pharmaceutical on Wikipedia, Google News & Yahoo Finance
- Kintor Pharmaceutical on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Luke Cheung 
Call Kintor Pharmaceutical at +86 512 ...
